Summary of DARA BIOSCIENCES, INC.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements and related Notes included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report includes forward-looking statements based on our current management's expectations. There can be no assurance that actual results, outcomes or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, among others, our limited operating history, unpredictability of future program dispositions and operating results, competitive pressures and the other potential risks and uncertainties discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2007.

Merger Transaction

On February 12, 2008, DARA BioSciences, Inc., formerly known as Point Therapeutics, Inc. ("we," "us" and "our" or the "Company"), completed the merger transaction (the "Merger") contemplated by the Agreement and Plan of Merger dated October 9, 2007, as amended December 19, 2007, among the Company, DP Acquisition Corp., a wholly-owned subsidiary of the Company ("Merger Sub"), and DARA BioSciences, Inc., a privately-held development stage pharmaceutical company based in Raleigh, North Carolina ("DARA").

Pursuant to the Merger, each share of DARA common stock and preferred stock issued and outstanding immediately prior to the effective time of the Merger ceased to be outstanding and was converted into the right to receive 1.031406 shares of Company common stock, plus cash in lieu of any fractional shares. As a result of the transaction, the former DARA stockholders received 96.4% of the Company's outstanding shares of common stock on a fully-diluted basis and Merger Sub merged with and into DARA, with DARA surviving as a wholly-owned subsidiary of the Company. Upon consummation of the Merger, the Company changed its name to DARA BioSciences, Inc.

For accounting purposes, the Merger was treated as a reverse acquisition with DARA being the accounting acquirer. Accordingly, the historical financial information in this Form 10-Q prior to the Merger is that of DARA and its consolidated subsidiaries and all references to the "Company" in this Form 10-Q relating to periods prior to the Merger refer to DARA (see Note 4).

Table of Contents

Overview

We are a Raleigh, North Carolina-based development stage pharmaceutical company that acquires promising therapeutic drug candidates from third parties and advances their clinical development for later sale or license to pharmaceutical companies. We operate a business model that focuses on the following:

º Obtaining patents for innovative drug candidates which we believe have value in the marketplace;

º Utilizing a small group of talented employees to develop those ideas through proof of concept in patients (generally through phase 2a clinical trials) by working with strategic outsource partners; and

º Licensing the resulting product to a strong pharmaceutical partner to commercialize. We do not intend to fully develop, obtain clearance from the U.S. Food and Drug Administration ("FDA") and then market the drug candidates we are developing.

We hire experts with strong project management skills in specific disciplines we believe are important to maintain within our company. We contract with and manage strong outsource partners to complete the necessary development work. This permits us to avoid incurring the cost of buying or building laboratories, manufacturing facilities or clinical research operation sites. It allows us to control our annual expenses and to optimize resources.

After we establish proof of concept for an innovative drug candidate, we seek a strong pharmaceutical partner to license the drug candidate and to commercialize it after regulatory approval. The success of our business is highly dependent on the marketplace value of our drug candidates, the related patents we obtain and our ability to find strong commercial partners to successfully commercialize the drug candidates.

We generally in-license drug candidates that are prepared to enter pre-clinical studies prior to being submitted for an Investigational New Drug application ("IND") (which is part of the process to get approval from the FDA for marketing a new prescription drug in the U. S.). Operationally we advance the development of our drug candidates from the stage we in-license the compound, typically at the pre-clinical stage of development, to obtain FDA approval of an IND application, test the drug candidates in Phase 1 and Phase 2 clinical trials and seek to license the drug candidate or find a collaborative partner who would further the development of the compound in later stage trials and commercialize it. Key indicators to evaluate our success are how our drug candidates advance through the drug development process, and ultimately, if we are successful in negotiating collaborations, licenses, or sales agreements with larger pharmaceutical companies for our drug candidates. In order to successfully achieve these goals, having sufficient liquidity is important since we do not have a recurring sales or revenue stream to provide such working capital.

We have not generated any revenue from operations to date. We have liquidated or distributed to our stockholders some of our investments made in other companies. To date, we have received net proceeds from the sale of those assets in the amount of approximately $5,650,000. These proceeds together with capital raised from the sale of our securities have been our primary source of working capital.

We expect to continue to incur operating losses over the next several years as we complete the development of our current portfolio of drug candidates and acquire and develop new drug candidates. Our results may vary depending on many factors, including pre-clinical and clinical test results, the performance of our strategic outsource partners and the progress of licensing activities with pharmaceutical partners.

Status of our Drug Candidates

We currently have a portfolio of five programs with drug candidates for the treatment of neuropathic pain, type 2 diabetes and psoriasis. In the third quarter we have focused our resources towards the development of our two most advanced programs, KRN5500 and DB959. Due to this allocation of resources, development of our other three programs DB160, DB900 and DB200, has been significantly delayed. Based on our present working capital, we believe that we have sufficient working capital to maintain our existing, most advanced programs, KRN5500 and DB959 into the first quarter of 2009 and that we will require additional funding to meet our working capital needs to progress those programs to a liquidity event through a collaboration, sale or out-license. A brief discussion of the status of each of our drug candidates follows.

KRN5500

KRN5500 is a drug candidate for the treatment of neuropathic pain in cancer patients. An active component of KRN5500 has been shown to inhibit nerve cell pain signals. The primary segment of this market being targeted is chemotherapy-induced neuropathic pain. The drug candidate is presently being tested in a Phase 2a clinical trial in cancer patients with neuropathic pain to assess its safety and efficacy. This trial is expected to be completed in the fourth quarter of 2008. A second larger Phase 2 trial is planned for initiation in 2009 assuming sufficient additional funding is secured.

We incurred approximately $167,000 and $769,000 in development costs associated with the development of KRN5500 for the three and nine month periods ended September 30, 2008, respectively, and we have incurred costs of approximately $2.8 million from inception to date. We estimate the market potential for chemotherapy-induced neuropathy to be roughly $1.6 billion in 2014.

Table of Contents

DB959

DB959 is a PPAR††† agonist for the treatment of type 2 diabetes. This compound activates genes involved in the metabolism of sugars and fats thereby improving the body's ability to regulate blood sugar. We are developing this drug candidate as a once-daily oral therapy. Our review of non-clinical data indicates that this drug candidate is a potential leading successor to Avandia® and Actos® because, among other indications, it increases good HDL cholesterol and lowers triglycerides better than Avandia® with greater cardiac safety and less weight gain. We expect to file an IND application to the FDA during the fourth quarter of 2008.

Our development work is being conducted under an exclusive worldwide license to develop and commercialize the drug candidate from Bayer Pharmaceuticals Corp. This license, which was entered into in October 2007, gives the Company rights to over 2,000 compounds with agonist activities toward multiple PPAR sub-types. On October 24, 2008, in accordance with the terms of this license, we provided Bayer with written notice of our intent to pursue a sublicense of our rights under the agreement to a third party for purposes of enabling such third party to commercialize "Licensed Products" (as such term is defined in the agreement). Under the terms of the license agreement, unless Bayer exercises certain rights of first refusal provided to it under the agreement and we reach agreement with Bayer concerning commercialization of Licensed Products, we will be permitted to enter into an agreement with a third party concerning commercialization of Licensed Products.

We incurred approximately $1.7 million and $2.5 million in direct outside development costs associated with the development of DB959 for the three and nine month periods ended September 30, 2008, respectively, and we have incurred costs of approximately $2.5 million from inception to date. We estimate the market potential for the PPAR agonist segment of type 2 diabetes market to be roughly $5.4 billion in 2010.

DB160

DB160 is a DPP-IV inhibitor for the treatment of type 2 diabetes. DDP-IV is an enzyme that inactivates a key hormone involved in promoting control of blood sugar levels thus giving diabetics better control of their blood sugar levels. The Company is developing this drug candidate as a once-daily oral therapy. We are currently evaluating the competitive environment for DB160 and potential positioning of the compound for other indications. During this ongoing evaluation we have focused our resources on other drug development programs. If our evaluation concludes that further development is warranted we would expect to file an IND application to the FDA during third quarter of 2009 assuming sufficient additional funding is secured. Our development work is being conducted under an exclusive worldwide license to develop and commercialize the drug candidate from Nuada, LLC.

We incurred approximately $229,000 and $1.3 million in direct outside development costs associated with the development of DB160 for the three and nine month periods ended September 30, 2008, respectively, and we have incurred costs of approximately $2.2 million from inception to date. We estimate the market potential for the DPP-IV inhibitor segment of the type 2 diabetes market to be roughly $5.1 billion in 2016.

DB900

DB900 is a series of compounds which are PPAR††††† agonists for the treatment of type 2 diabetes. This compound activates genes involved in the metabolism of sugars and fats thereby improving the body's ability to regulate blood sugar. A clinical candidate will be selected from a number of strong lead compounds. These compounds have the potential to raise good HDL cholesterol, lower bad LDL cholesterol and lower triglycerides with potential greater efficacy than DB959 as well as the potential to deliver weight loss. This program is currently not being resourced. Development will not be re-initiated until sufficient additional funding is secured. Our development work is being conducted under an exclusive worldwide license to develop and commercialize the drug candidate from Bayer Pharmaceuticals Corp.

We incurred approximately $23,000 and $86,000 in direct outside development costs associated with the development of DB900 series compounds for the three and nine month periods ended September 30, 2008, respectively, and we have incurred costs of approximately $92,000 from inception to date. We estimate the market potential for the PPAR agonist segment of type 2 diabetes market to be roughly $5.4 billion in 2010.

DB200

DB200 refers to a series of compounds we have which are inhibitors of CPT-1 for the topical treatment of psoriasis. This drug candidate has the potential to inhibit inflammation and the proliferation of skin cells thus resulting in decreased reddening and less flaking of the skin. A clinical candidate may be selected from a number of strong lead compounds. This program is currently not being resourced. Development will not be re-initiated until sufficient additional funding is secured. We expect to file an IND application to the FDA in 2010 assuming sufficient additional funding is secured. There are no third party licenses associated with this program.

We incurred approximately $180,000 and $328,000 in direct development costs associated with the development of DB200 series compounds for the three and nine month periods ended September 30, 2008, respectively, and we have incurred costs of approximately $363,000 from inception to date. We estimate the market potential for the topical agent segment of the psoriasis market to be roughly $3.6 billion in 2014.

Other

Prior to the Merger, we studied talabostat (acquired in the merger with Point Therapeutics, Inc.) in a number of human clinical trials as a potential therapy in late-stage cancers. In May 2007, the talabostat clinical development program was put on clinical hold by the FDA as a result of interim clinical results related to Phase 3 talabostat studies as a potential treatment for patients in advanced non-small cell lung cancer. We have determined that further development of talabostat is not warranted at this time and our resources are being applied to our other programs.

Table of Contents

Investments

Prior to 2007, we made investments in several companies. As a result, we currently hold investments in the following companies:

? SurgiVision, Inc. is developing "real-time" devices to be used with Functional MRI Technology.The company is targeting clinical solutions in areas such as MRI-guided deep brain stimulation and cardiac ablation to treat atrial fibrillation. This investment represents approximately 10% of the outstanding shares of SurgiVision at September 30, 2008.

? Cardiovascular Solutions, Inc., formerly known as Medeikon Corporation is developing technology focusing on the diagnostics of vulnerable plaque using an optical detection system. This investment represents approximately 25.4% of the outstanding shares of Cardiovascular Solutions, Inc. at September 30, 2008.

? MiMedx Group, Inc. (MDXG.OB) is developing products primarily for use by musculoskeletal specialists in both surgical and non-surgical therapy. This investment represents approximately 1.5 % of the outstanding shares of MiMedx Group, Inc. at September 30, 2008.

Critical Accounting Policies and Significant Judgments and Estimates

This Management's Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to research and development expenses, accrued expenses and share-based compensation. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

Research and Development Expenses

We expense research and development expenses when incurred. The cost of certain research programs, such as patient recruitment and related supporting functions for clinical trials, are based on reports and invoices submitted by the contract research organization ("CRO") assisting us in conducting the clinical trial. These expenses are based on patient enrollment as well as costs consisting primarily of payments made to the CRO, clinical centers, investigators, testing facilities and patients for participating in our clinical trials. Certain research and development costs must be prepaid which, if the research and development work ceases to progress for whatever reason, are not repayable to us. In such cases, those costs are expensed when paid.

Accrued Expenses

As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when invoices have not yet been sent and we have not otherwise been notified of actual cost. The majority of our service providers invoice monthly in arrears for services performed. We make estimates of accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:

? fees paid to CROs in connection with preclinical and toxicology studies and clinical trials;

? fees paid to investigative sites in connection with clinical trials;

? fees paid to contract manufacturers in connection with the production of raw materials, drug substance and drug products; and

? professional service fees.

Table of Contents

Share-Based Compensation

Share-based compensation is accounted for using the fair value based method prescribed by SFAS No. 123R, Accounting for Share-Based Payment ("SFAS 123R"). For stock and stock-based awards issued to employees, a compensation charge is recorded against earnings based on the fair value of the award. For transactions with non-employees in which services are performed in exchange for the Company's common stock or other equity instruments, the transactions are recorded on the basis of the fair value of the service received or the fair value of the equity instruments issued, whichever is more readily measurable at the date of issuance. Our Company's share-based compensation transactions for employees resulted in compensation expense of $666,228 and $143,587 for the three months ended September 30, 2008 and 2007, respectively, and $1,095,080 and $387,792 for the nine months ended September 30, 2008 and 2007, respectively. The Company issued 35,000 restricted shares to a new board director during the three months ended September 30, 2008, of which 25% vested immediately. The remaining issued shares vest pro rata over the next three years on the anniversary of the director's appointment. The Company issued 220,000 restricted shares to an investor relations company for services contracted. The Company recognized stock-based compensation expense for awards to non-employees totaling $20,374 for the three and nine months ended September 30, 2008. The Company recognized stock-based compensation for awards to certain board of directors of $28,157 and $99,731 for the three and nine months ended September 30, 2008, respectively. The Company recognized stock-based compensation expense to non-employees of $0 and $1,706 for the three and nine months ended September 30, 2007. The Company had no stock-based compensation expense for board of directors for the three and nine months ended September 30, 2007.

Results of Operations

Three Months Ended September 30, 2008 Compared to Three Months Ended September 30, 2007

Research and development expenses increased from approximately $815,000 for the three months ended September 30, 2007 to approximately $2.7 million for the corresponding 2008 period, primarily as a result of increased expenses incurred in continuing development of the neuropathic pain compound and initiating the development of the following new programs that the Company did not have in the three months ended September 30, 2007: DB959, DB200 and DB900.

General and administrative expenses consist primarily of salaries and benefits, professional fees related to administrative, finance, human resource, legal and information technology functions and patent costs. In addition, general and administrative expenses include allocated facility, basic operational and support costs and insurance costs. General and administrative expenses increased from approximately $775,000 for the three months ended September 30, 2007 to approximately $1.3 million for the corresponding 2008 period, primarily as a result of costs associated with being a public company.

Other (expense) income, net reflects non-operating activities associated with investments and dispositions on investments made in collaborations with other companies. Other (expense) income, net decreased from income of approximately $197,000 for the three months ended September 30, 2007 to approximately $6,000 for the corresponding 2008 period. This fluctuation was due to the variance in interest income earned.

Nine Months Ended September 30, 2008 Compared to Nine Months Ended September 30, 2007

Research and development expenses increased from approximately $2.2 million for the nine months ended September 30, 2007 to approximately $6.2 million for the corresponding 2008 period, primarily as a result of increased expenses incurred in continuing development of the neuropathic pain compound and initiating the development of the following new programs that the Company did not have in the nine months ended September 30, 2007: DB959, DB200 and DB900.

General and administrative expenses consist primarily of salaries and benefits, professional fees related to administrative, finance, human resource, legal and information technology functions and patent costs. In addition, general and administrative expenses include allocated facility, basic operational and support costs and insurance costs. General and administrative expenses increased from approximately $1.8 million for the nine months ended September 30, 2007 to approximately $3.5 million for the corresponding 2008 period, primarily as a result of the substantial expenses we incurred in the first quarter of 2008 in connection with the Merger and becoming a public company, as well as an increase of two employees, the increase in occupancy costs associated with the new office facilities and the associated overhead.

Other (expense) income, net reflects non-operating activities having to do with investments and dispositions on investments made in collaborations with other companies. Other (expense) income, net decreased from approximately $4.9 million for the nine months ended September 30, 2007 to approximately $115,000 for the corresponding 2008 period. This decrease was primarily due to there being no recognized gains on nonmonetary assets or from the sale of securities in the nine months ended September 30, 2008 compared to recognizing (1) a gain on nonmonetary assets of approximately $2,658,000 as a result of our distribution of a dividend of shares of SurgiVision stock to stockholders and option holders and (2) a gain from the sale of securities of approximately $1,773,000 as a result of our sale of our remaining investment in Medivation, Inc. during the nine months ended September 30, 2007.

Table of Contents

Liquidity and Capital Resources

Overview

From inception through September 30, 2008, we have financed our operations primarily from the net proceeds of (1) private placements of equity securities, through which we raised approximately $23,295,000, and (2) the sale of securities held in subsidiary companies, through which we raised approximately $5,650,000.

At September 30, 2008, our principal sources of liquidity were our cash and cash equivalents which totaled approximately $1.1 million. As of September 30, 2008, we had net working capital of approximately $1.2 million. Our cash resources have been used to acquire licenses, fund research and development activities, capital expenditures, and general and administrative expenses. Over the next several years, we expect to incur substantial additional research and development costs, including costs related to preclinical and clinical trials, increased administrative expenses to support our research and development operations and increased capital expenditures, and various equipment needs and facility improvements. It should be noted that in accordance with applicable accounting rules, our balance sheet at September 30, 2008 includes investment securities available for sale of approximately $1.6 million. However, these securities will not be freely saleable by us until February 2009.

On October 21, 2008, we entered into a Securities Purchase Agreement with certain investors in connection with a registered direct offering (the "Offering") of up to 8,500,000 shares of the Company's common stock and up to 13,600,000 warrants (less 850,000 Class A Warrants to Gilford Securities, Inc., the placement agent) to purchase shares of the Company's common stock. The terms of the Offering provide for the common stock and warrants to be sold in units for $1.00 per unit, with each unit consisting of (1) one share of common stock,
(2) a Class A Warrant to purchase one share of common stock for each unit purchased at the greater of (a) the consolidated closing bid price on the NASDAQ Capital Market on the trading day immediately preceding the applicable closing date plus $.01 and (b) $1.30 or, if higher, the exercise price for Class A Warrants set at an earlier closing and (3) a Class B Warrant to purchase one-half of a share of common stock for each unit purchased at $2.25 per share. Class A Warrants are exercisable beginning six months after the date of issuance and expire five years after they first become exercisable. Class B Warrants are exercisable beginning 12 months after the date of issuance and expire five years after they first become exercisable. The shares of common stock and Warrants in the Offering are being offered pursuant to an effective shelf registration statement on Form S-3, which was initially filed with the SEC on April 9, 2008 and declared effective on April 18, 2008 (File No.333-150150).

The Company sold 2,255,000 units at an initial closing that was completed on October 21, 2008 for cash proceeds (net of cash fees payable to the placement agent) of $2,029,500. There can be no assurance that we will be able to sell any . . .